研究参与者对阿尔茨海默氏症疾病精确诊断的观点
Hadley Stevens Smith1,2, Jill O Robinson1, Ariel Levchenko1
1Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, TX, USA.
Journal of Alzheimer's disease : JAD
|January 22, 2024
概括
参与者从PET扫描和基因测试中了解了他们患阿尔茨海默病 (AD) 的风险,报告了积极的心理结果和高的自我效能. 这项研究为AD的精确诊断的临床实施提供了信息.
科学领域:
- 神经学 神经学
- 遗传学 遗传学 是一个
- 医疗成像医学成像
背景情况:
- 了解患者对阿尔茨海默病 (AD) 风险信息的反应对于实施精确诊断至关重要.
- 疾病修饰疗法的进步需要对AD风险进行明确的沟通.
- 参与者理解和AD风险披露的心理影响是关键考虑因素.
研究的目的:
- 评估参与者对粉样质正子辐射断层扫描 (PET) 影像成像结果对AD风险的理解.
- 评估参与者的自我效能,心理影响和结果披露的经验.
- 为了衡量对AD风险遗传测试的兴趣.
主要方法:
- 对88名接受AD临床评估并接受PET成像的人进行调查.
- 使用费舍尔精确测试对近期调查项目的分析.
- 开放式响应的定性编码,以了解参与者的观点.
主要成果:
- 大多数参与者报告说,他们对PET结果有主观的理解,并对未来的规划感到有权力.
- 负面PET结果的参与者比积极结果的参与者更频繁地体验到缓解和快乐.
- 人们注意到对基因测试的高度兴趣,以告知医疗决策和家庭风险评估.
结论:
- 参与者对他们的PET结果表现出高度的主观理解和自我有效性.
- 学习PET结果并没有导致显著的负面心理影响.
- 对AD风险评估和规划的基因测试有很大的兴趣.
更多相关视频
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.1K
06:46Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
12.2K
相关概念视频
01:26Alzheimer's Disease: Overview
490
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
490
01:22Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195